Transient exposure to elastase induces mouse aortic wall smooth muscle cell production of MCP-1 and RANTES during development of experimental aortic aneurysm

Journal of Vascular Surgery

Volumn 38, Issue 1, 2003, Pages 138-146

  Colonnello, Jamie S ^a   Hance, Kirk A ^a   Shames, Murray L ^a   Wyble, Charles W ^a   Ziporin, Scott J ^a   Leidenfrost, Jeremy E ^a   Ennis, Terri L ^a   Upchurch Jr , Gilbert R ^b   Thompson, Robert W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELASTASE; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; BETA CHEMOKINE; PANCREATIC ELASTASE;

ABDOMINAL AORTA ANEURYSM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA WALL; ARTICLE; CELL COUNT; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPOSURE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; ABDOMINAL AORTA; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; DRUG EFFECT; METABOLISM; PATHOPHYSIOLOGY; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; CELLS, CULTURED; CHEMOKINE CCL2; CHEMOKINES, CC; MALE; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; MUSCLE, SMOOTH, VASCULAR; PANCREATIC ELASTASE; RANTES;

EID: 0037771323     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0741-5214(03)00125-3     Document Type: Article

References (47)

1. Brophy CM, Reilly JM, Smith GJ, Tilson MD. The role of inflammation in nonspecific abdominal aortic aneurysm disease. Ann Vasc Surg 1991; 5:229-33.
2. Koch AE, Haines GK, Rizzo RJ, Radosevich JA, Pope RM, Robinson PG, et al. Human abdominal aortic aneurysms: immunophenotypic analysis suggesting an immune-mediated response. Am J Pathol 1990; 137:1199-1213.
3. Shah PK. Inflammation, metalloproteinases, and increased proteolysis: an emerging pathophysiological paradigm in aortic aneurysm. Circulation 1997;96:2115-7.
4. Davies MJ. Aortic aneurysm formation: lessons from human studies and experimental models. Circulation 1998;98:193-5.
5. Thompson RW. Chronic inflammation, matrix metalloproteinases and medial smooth muscle cell apoptosis: interrelated factors in the progression of abdominal aortic aneurysms. J Vasc Surg 1998;27:1179-81.
6. Thompson RW, Parks WC. Role of matrix metalloproteinases in abdominal aortic aneurysms. Ann N Y Acad Sci 1996;800:157-74.
7. Thompson RW. Basic science of abdominal aortic aneurysms: emerging therapeutic strategies for an unresolved clinical problem. Curr Opin Cardiol 1996;11:504-18.
8. Thompson RW, Baxter BT. MMP inhibition in abdominal aortic aneurysms: rationale for a prospective randomized clinical trial. Ann N Y Acad Sci 1999;878:159-78.
9. Dal Canto AJ, Swanson PE, O'Guin AK, Speck SH, Virgin HW. IFN-gamma action in the media of the great elastic arteries, a novel immunoprivileged site. J Clin Invest 2001;107:R15-22.
10. Senior RM, Griffin GL, Mecham RP. Chemotactic activity of elastin-derived peptides. J Clin Invest 1980;66:859-62.
11. Senior RM, Griffin GL, Mecham RP, Wrenn DS, Prasad KU, Urry DW. Val-Gly-Val-Ala-Pro-Gly, a repeating peptide in elastin, is chemotactic for fibroblasts and monocytes. J Cell Biol 1984;99:870-4.
12. Hance KA, Tataria M, Ziporin SJ, Lee JK, Thompson RW. Monocyte chemotactic activity in human abdominal aortic aneurysms: role of elastin degradation peptides and the 67-kD cell surface elastin receptor. J Vasc Surg 2002;35:254-61.
13. Anidjar S, Salzmann JL, Gentric D, Lagneau P, Camilleri JP, Michel JB. Elastase induced experimental aneurysms in rats. Circulation 1990;82:973-81.
14. Anidjar S, Dobrin PB, Eichorst M, Graham GP, Chejfec G. Correlation of inflammatory infiltrate with the enlargement of experimental aortic aneurysm. J Vasc Surg 1992;16:139-47.
15. Halpern VJ, Nackman GB, Gandhi RH, Irizarry E, Scholes JV, Ramey WG, et al. The elastase infusion model of experimental aortic aneurysms: synchrony of induction of endogenous proteinases with matrix destruction and inflammatory cell response. J Vasc Surg 1994;20:51-60.
16. Holmes DR, Petrinec D, Wester W, Thompson RW, Reilly JM. Indomethacin prevents elastase-induced abdominal aortic aneurysms in the rat. J Surg Res 1996;63:305-9.
17. Ricci MA, Strindberg G, Slaiby JM, Guibord RS, Bergersen LJ, Nichols PP, et al. Anti-CD18 monoclonal antibody slows experimental aortic aneurysm expansion. J Vasc Surg 1996;23:301-7.
18. Petrinec D, Liao S, Holmes DR, Reilly JM, Parks WC, Thompson RW. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: presentation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg 1996;23:336-46.
19. Dobrin PB. Animal models of aneurysms. Ann Vasc Surg 1999;13:641-8.
20. Pyo R, Lee JK, Shipley JM, Curd JA, Mao D, Ziporin SJ, et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest 2000;105:1641-9.
21. Koch A, Kunkel S, Pearce W, Shah M, Parikli D, Evanoff H, et al. Enhanced production of the chemotactic cytokines interleukin-8 and monocyte chemoattractant protein-1 in human abdominal aortic aneurysms. Am J Pathol 1993;142:1423-31.
22. Franklin IJ, Walton LJ, Greenhalgh RM, Powell JT. The influence of indomethacin on the metabolism and cytokine secretion of human aneurysmal aorta. Eur J Vasc Endovasc Surg 1999;18:35-42.
23. Terkeltaub R, Boisvert WA, Curtiss LK. Chemokines and atherosclerosis. Curr Opin Lipidol 1998;9:397-405.
24. Luster A. Chemokines: Chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436-45.
25. Wang M, Shen W, Su S. Chemokines and their role in cardiovascular diseases. Trends Cardiovasc Med 1998;8:169-74.
26. Kunkel S. Through the looking glass: the diverse in vivo activities of chemokines. J Clin Invest 1999;104:1333-4.
27. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000;18:217-42.
28. Lee JK, Borhani M, Ennis TL, Upchurch GRJ, Thompson RW. Experimental abdominal aortic aneurysms in mice lacking expression of inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol 2001; 21:1393-1401.
29. Glantz SA. Primer of biostatistics. 5th ed. New York: McGraw-Hill; 2002.
30. Yla-Herttuala S, Lifton B, Rosenfeld M, Sarkioja T, Yoshimura T, Leonard E, et al. Expression of MCP-1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 1991;88:5252-6.
31. Kowala M, Recce R, Beyer S, Gu C, Valentine M. Characterization of atherosclerosis in LDL receptor knockout mice: macrophage accumulation correlates with rapid and sustained expression of aortic MCP-1/JE. Atherosclerosis 2000;149:323-30.
32. Aiello R, Bourassa P-A, Lindsey S, Seng W, Natoli E, Rollins B, et al. MCP-1 accelerates atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 1999;19:1518-25.
33. Nelken N, Coughlin S, Gordon D, Wilcox J. MCP-1 in human atheromatous plaques. J Clin Invest 1991;88:1121-7.
34. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998;394:894-7.
35. Yu X, Dluz S, Graves D, Zhang L, Automates H, Hollander W, et al. Elevated expression of MCP-1 by vascular smooth muscle cells in hypercholesterolemic primates. Proc Natl Acad Sci USA 1992;89:6953-7.
36. Taubman M, Rollins B, Poon M, Marmur J, Green R, Berk B, et al. JE mRNA accumulates rapidly in aortic injury and in PDGF-stimulated vascular smooth muscle cells. Circ Res 1992;70:314-25.
37. Matsumori A, Furukawa Y, Hashimoto T, Yoshida A, Ono K, Shioi T, et al. Plasma levels of monocyte chemotactic and activating factor/ monocyte chemoattractant protein-1 are elevated in patients with acute myocardial infarction. J Mol Cell Cardiol 1997;29:419-23.
38. Aukrust P, Ueland T, Muller F, Andreassen A, Nordoy I, Aas H, et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 1998;97:1136-43.
39. Cipollone F, Marini M, Fazia M, Pini B, Iezzi A, Reale M, et al. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol 2001;21:327-34.
40. Gu L, Okada Y, Clinton S, Sukhova G, Libby P, Rollins B. Absence of MCP-1 reduces atherosclerosis in LDL receptor-deficient mice. Mol Cell 1998;2:275-81.
41. Furukawa Y, Matsumori A, Ohashi N, Shioi T, Ono K, Harada A, et al. Anti-MCP-1/MCAF antibody inhibits neointimal hyperplasia in injured rat carotid arteries. Circ Res 1999;84:306-14.
42. Aiello RJ, Bourassa PA, Lindsey S, Weng W, Natoli E, Rollins BJ, et al. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 1999;19:1518-25.
43. Roque M, Kim WJ, Gazdoin M, Malik A, Reis ED, Fallon JT, et al. CCR2 deficiency decreases intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol 2002;22:554-9.
44. Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and transforming growth factor beta-1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996;271:17779-84.
45. Yamamoto T, Eckes B, Manch C, Hartmann K, Krieg T. Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1 alpha loop. J Immunol 2000;164:6174-9.
46. Taub DD, Oppenheim JJ. Chemokines, inflammation and the immune system. Ther Immunol 1994;1:229-46.
47. Pattison JM, Nelson PJ, Huie P, Sibley RK, Krensky AM. RANTES chemokine expression in transplant-associated accelerated atherosclerosis. J Heart Lung Transplant 1996;15:1194-9.